A well-known billionaire investor bought more shares last week in a High Point-based company developing drugs to treat Alzheimer’s disease and diabetes, according to a filing Monday with the Securities and Exchange Commission.

Ronald Perelman’s company MacAndrews & Forbes Inc. purchased 60,000 shares of VTV Therapeutics Inc. on Aug. 10 at an average price of $3.98.

Then, the company purchased another 25,000 shares on Aug. 11 at an average price of $4.48. In total, it spent more than $350,000 to purchase additional stock.

The company now owns 2.46 million shares of the company’s Class A stock worth more than $11.6 million based on Monday’s closing price.

VTV Therapeutics closed Monday at $4.72, up 25 cents, or 5.6 percent.

Perelman is chairman and chief executive officer of the company, which has a diversified portfolio of public and private companies.

MacAndrews & Forbes’s investments include AM General, Deluxe Entertainment Services Group Inc., Harland Clarke, Merisant, Revlon Inc., Scantron, Scientific Games Corp., SIGA Technologies, Inc., and Valassis.

According to the company’s proxy statement, 23.1 million shares of its Class B common stock is also held by MacAndrews & Forbes, and 655,721 shares of its Class B stock is held by Perelman.

At the American Diabetes Association meeting in June, VTV Therapeutics presented updates from its Phase 2 clinical study of its diabetes drug that may expand the treatment options for patients with Type 2 diabetes.

VTV also completed enrollment of Part B of its Phase 3 study of its Alzheimer’s drug, and expects data from Part A early next year.

Earlier this month, the company received a U.S. patent for its Alzheimer’s treatment.